Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary

Good morning, ladies and gentlemen, and welcome to Heron Therapeutics 2020 Annual Meeting of Stockholders. My name is Barry Quart, and I serve as President, Chief Executive Officer of Heron Therapeutics. I'll be presiding over this meeting. At this time, I call the meeting to order. I will act as Chairman of the meeting. The Board has appointed David Szekeres to serve as our inspector of elections. We are pleased to hold this meeting virtually for the first time this year as we aim to increase access and participation and to do our part to limit travel and large physical gatherings in light of the ongoing pandemic resulting from COVID-19. Stockholders may submit questions related to matters being voted on during the meeting in the space provided on the virtual shareholder meeting screen. Questions should pertain to the proposals being considered at the particular time and should be submitted before the polls close. As noted in the notice and proxy statement previously provided to stockholders, the record date for voting at this meeting was the close of business on April 20, 2020. A list of registered stockholders on the record date is available for inspection by stockholders during the meeting via the link on your virtual stockholder meeting screen. Notice of the stockholder meeting was made available online and mailed on or about May 8, 2020, to all stockholders entitled to vote as of the record date, and the transfer agent has delivered an affidavit of mailing to show that notice of this meeting was given. As of the record date, there were 90,642,154 shares of common stock outstanding and entitled to vote. We are informed by the inspector of elections that there are represented, in person or by proxy, at least 77,611,315 shares of common stock or approximately 85.62% of all shares entitled to vote at this meeting. Based on the percentage of total shares of the company held by holders of record now present at the meeting, a quorum is present. The meeting is now duly convened for the purpose of transacting business properly before it. If you have already submitted your proxy card, you shouldn't vote again unless you wish to revoke your proxy or change your vote. At this meeting, stockholders will vote on 3 proposals described in the proxy statement. Proposal 1 is election of 7 director nominees. Proposal 2 is ratification of OUM & Co. LLP as Heron's independent registered public accounting firm for the year ending December 31, 2020. And proposal #3 is advisory vote to approve compensation paid to our executive officers during the year ended December 31, 2019. The Board recommends that you vote for all 7 director nominees and for proposals 2 and 3. If you have not already voted by proxy, please vote electronically at this time via the virtual shareholder meeting screen. The polls are open for each matter to be voted upon for the moment. [Voting]

Okay. The polls are now officially closed. The final vote totals will be published in a current report on Form 8-K that we expect to file within 4 business days. Will the inspector of elections please report the preliminary vote count? David?

Thank you, Barry. Based on a preliminary tally of votes cast, I declare that the 7 director nominees named in the proxy statement have been elected to serve until the 2021 Annual Meeting of Stockholders and until their successors are duly elected and qualified. The appointment of OUM & Co. LLP as the company's independent registered public accounting firm for the year ended December 31, 2020, has been ratified. And compensation paid to our named executive officers during the year ended December 31, 2019, has been approved on an advisory basis. Barry?

Thank you. Due to the proximity of our upcoming June 26 PDUFA date for HTX-011, we will not be holding a general question-and-answer session. There being no further business, this concludes our annual meeting, and the meeting is now adjourned. Thank you for attending.